JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB154744

Anti-LXN/TCI antibody

Be the first to review this product! Submit a review

|

(3 Publications)

Rabbit Polyclonal LXN/TCI antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Mouse, Human, Rat samples. Cited in 3 publications. Immunogen corresponding to Recombinant Fragment Protein within Human LXN aa 1 to C-terminus.

View Alternative Names

Latexin, Endogenous carboxypeptidase inhibitor, Protein MUM, Tissue carboxypeptidase inhibitor, ECI, TCI, LXN

7 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LXN/TCI antibody (AB154744)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LXN/TCI antibody (AB154744)

Immunohistochemical analysis of paraffin-embedded FaDu xenograft labeling LXN/TCI with ab154744 at 1/500 dilution.

Immunocytochemistry/ Immunofluorescence - Anti-LXN/TCI antibody (AB154744)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-LXN/TCI antibody (AB154744)

Immunofluorescent analysis of paraformaldehyde-fixed mouse embryonic stem cells D3 labeling LXN/TCI with ab154744 at 1/200 dilution. Lower panel is co-stained with Hoechst 33342.

Western blot - Anti-LXN/TCI antibody (AB154744)
  • WB

Unknown

Western blot - Anti-LXN/TCI antibody (AB154744)

12% SDS PAGE

All lanes:

Western blot - Anti-LXN/TCI antibody (ab154744) at 1/1000 dilution

Lane 1:

293T whole cell lysate at 30 µg

Lane 2:

HeLa S3 whole cell lysate at 30 µg

Predicted band size: 26 kDa

false

Western blot - Anti-LXN/TCI antibody (AB154744)
  • WB

Unknown

Western blot - Anti-LXN/TCI antibody (AB154744)

12% SDS PAGE

All lanes:

Western blot - Anti-LXN/TCI antibody (ab154744) at 1/1000 dilution

All lanes:

mouse brain whole cell lysate at 50 µg

Predicted band size: 22 kDa,26 kDa,32 kDa

false

Western blot - Anti-LXN/TCI antibody (AB154744)
  • WB

Supplier Data

Western blot - Anti-LXN/TCI antibody (AB154744)

Samples were separated by 12% SDS-PAGE.

All lanes:

Western blot - Anti-LXN/TCI antibody (ab154744) at 1/1000 dilution

All lanes:

Rat brain tissue lysates at 50 µg

Secondary

All lanes:

HRP conjugated anti rabbit IgG antibody

Predicted band size: 26 kDa

false

Western blot - Anti-LXN/TCI antibody (AB154744)
  • WB

Supplier Data

Western blot - Anti-LXN/TCI antibody (AB154744)

Samples were separated by 12% SDS-PAGE.

All lanes:

Western blot - Anti-LXN/TCI antibody (ab154744) at 1/1000 dilution

All lanes:

Rat heart tissue lysates at 50 µg

Secondary

All lanes:

HRP conjugated anti rabbit IgG antibody

Predicted band size: 26 kDa

false

Western blot - Anti-LXN/TCI antibody (AB154744)
  • WB

Supplier Data

Western blot - Anti-LXN/TCI antibody (AB154744)

Samples were separated by 12% SDS-PAGE.

All lanes:

Western blot - Anti-LXN/TCI antibody (ab154744) at 1/3000 dilution

Lane 1:

Wild-type (WT) HeLa cell extracts at 30 µg

Lane 2:

LXN knockout (KO) HeLa cell extracts at 30 µg

Secondary

All lanes:

HRP-conjugated anti-rabbit IgG antibody

Predicted band size: 26 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Human, Rat

Applications

IHC-P, WB, ICC/IF

applications

Immunogen

Recombinant Fragment Protein within Human LXN aa 1 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

Q9BS40

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/1000", "IHCP-species-notes": "<p>Perform heat mediated antigen retrieval before commencing with IHC staining protocol using 10mM Citrate buffer (pH6.0) or Tris-EDTA buffer (pH8.0).</p>" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100 - 1/1000", "ICCIF-species-notes": "<p></p>", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Rat": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7 Preservative: 0.01% Thimerosal (merthiolate) Constituents: 10% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

LXN also known as Latexin or TCI (Tryptase Inhibitor Complex) is a protein with a molecular mass of approximately 24 kDa. LXN acts as an inhibitor of carboxypeptidase A and is primarily involved in regulating protease activity. It is expressed mainly in the liver lung and kidney playing a significant role in protein degradation processes. LXN's inhibitory functions contribute significantly to cellular processes by modulating enzyme activity.
Biological function summary

LXN influences cell proliferation and differentiation. It participates in cellular protection mechanisms against enzymatic damage and balances protease and anti-protease activities in tissues. Although not part of a large complex LXN impacts various cellular events through its protease inhibitor function making it important in tissue homeostasis. Studies suggest its importance in maintaining cell viability and regulating cellular stress responses.

Pathways

LXN associates with pathways linked to inflammation and tissue remodeling with particular emphasis on the protease-antiprotease balance. LXN acts within the kallikrein-kinin system and relates to proteins such as carboxypeptidase A1 which it directly inhibits. Its modulation of these pathways is essential for normal physiological responses and protective mechanisms against tissue damage.

LXN has been linked to cancer and inflammation-related conditions. In cancer its regulation of protease activity can influence tumor growth and metastasis often interacting with proteins like tryptase. LXN's role in inflammation relates to conditions such as rheumatoid arthritis where its influence on the balance of proteases and inhibitors impacts tissue damage and repair processes. Further research into LXN's roles may help elucidate mechanisms driving these diseases offering potential therapeutic targets.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Hardly reversible, non-competitive, and potent inhibitor of CPA1, CPA2 and CPA4. May play a role in inflammation.
See full target information LXN

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Physiological reports 12:e70126 PubMed39532808

2024

Lack of adipocyte FAM20C improves whole body glucose homeostasis.

Applications

Unspecified application

Species

Unspecified reactive species

Liping Deng,Yanshan Huang,Feifei Zhao,Puxin Chen,Xiaohong Huang

Frontiers in oncology 11:681366 PubMed34136404

2021

N-Myristoylation by NMT1 Is POTEE-Dependent to Stimulate Liver Tumorigenesis Differentially Regulating Ubiquitination of Targets.

Applications

Unspecified application

Species

Unspecified reactive species

Guoqing Zhu,Feng Wang,Haojie Li,Xiao Zhang,Qi Wu,Ya Liu,Mingping Qian,Susu Guo,Yueyue Yang,Xiangfei Xue,Fenyong Sun,Yongxia Qiao,Qiuhui Pan

Cancer cell 37:21-36.e13 PubMed31935371

2020

An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates.

Applications

Unspecified application

Species

Unspecified reactive species

Jermaine Goveia,Katerina Rohlenova,Federico Taverna,Lucas Treps,Lena-Christin Conradi,Andreas Pircher,Vincent Geldhof,Laura P M H de Rooij,Joanna Kalucka,Liliana Sokol,Melissa García-Caballero,Yingfeng Zheng,Junbin Qian,Laure-Anne Teuwen,Shawez Khan,Bram Boeckx,Els Wauters,Herbert Decaluwé,Paul De Leyn,Johan Vansteenkiste,Birgit Weynand,Xavier Sagaert,Erik Verbeken,Albert Wolthuis,Baki Topal,Wouter Everaerts,Hanibal Bohnenberger,Alexander Emmert,Dena Panovska,Frederik De Smet,Frank J T Staal,Rene J Mclaughlin,Francis Impens,Vincenzo Lagani,Stefan Vinckier,Massimiliano Mazzone,Luc Schoonjans,Mieke Dewerchin,Guy Eelen,Tobias K Karakach,Huanming Yang,Jian Wang,Lars Bolund,Lin Lin,Bernard Thienpont,Xuri Li,Diether Lambrechts,Yonglun Luo,Peter Carmeliet
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com